Cost-effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States

Authors
Category Systematic review
JournalJournal of Managed Care and Specialty Pharmacy
Year 2017
This article has no abstract
Epistemonikos ID: 7e55dc60f9e04ae9ca42639472f2eec8806c8d8e
First added on: Feb 09, 2025